Drug intelligence / Profile preview

CLS014

Development stage: Unknown
Lead developer: Cellusion
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
Administration: Ophthalmic

Overview

CLS014 is an experimental cell therapy being developed by Cellusion in collaboration with the University of Tokyo for the treatment of metabolic diseases. The program utilizes Cellusion's proprietary FRiEND Tech (Function Regeneration in Endocrine and Neural Differentiation Technology) and Function Added CECSi Cells platforms. These technologies are designed to differentiate induced pluripotent stem cells (iPSCs) into functional cells capable of addressing endocrine and metabolic dysfunctions. As of 2024, CLS014 is in the research phase of development.

Targets

cfDNA (Cell-free DNA)

Beyond the preview

Go deeper on CLS014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLS014.

Explore the full profile